Bioventus (BVS) Cash from Financing Activities (2020 - 2026)

Bioventus (BVS) has 7 years of Cash from Financing Activities data on file, last reported at -$23.1 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 2543.93% year-over-year to -$23.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$86.2 million (down 74.59% YoY) and the FY2025 annual result came in at -$62.1 million, down 13.85% from the prior year.
• Cash from Financing Activities climbed to -$23.1 million in Q1 2026, from -$28.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $50.7 million in Q4 2022 to a low of -$62.2 million in Q3 2023.
• A 5-year average of -$6.1 million and a median of -$4.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 1265.53% — and 2024, when it tumbled 306007.14%.
• Tracing BVS's Cash from Financing Activities over 5 years: stood at -$5.4 million in 2022, then surged by 99.74% to -$14000.0 in 2023, then plunged by 306007.14% to -$42.9 million in 2024, then surged by 33.62% to -$28.4 million in 2025, then increased by 18.64% to -$23.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$23.1 million (Q1 2026), -$28.4 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.